Company news
Precigen, Inc. news in 2022
Precigen, Inc.'s news releases, calls and decks from 2022, newest first.
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 18, 2022
Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
December 11, 2022
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
November 8, 2022
Precigen to Announce Third Quarter 2022 Financial Results on November 9th
November 1, 2022
Precigen Names Rutul R. Shah Chief Operating Officer
September 20, 2022
Precigen to Participate in the 2022 Wells Fargo Healthcare Conference
August 31, 2022
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
August 21, 2022
Precigen Reports Second Quarter and First Half 2022 Financial Results
August 7, 2022
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th
July 31, 2022
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
July 4, 2022
Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit
June 26, 2022
Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference
May 16, 2022
Precigen Reports First Quarter 2022 Financial Results and Business Updates
May 8, 2022
Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia
April 3, 2022
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
January 11, 2022
Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022